Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Data Access

STOP-HCV has generated large volumes of data that will be made available to the wider scientific community for research purposes.

An overview of the types of data available can be found in the table below. For further details regarding this data please contact the Lead PI for the STOP-HCV Consortium, Professor Ellie Barnes (ellie.barnes@ndm.ox.ac.uk). Access to STOP-HCV data is via application (data request form) and requests will be reviewed by the STOP-HCV Data Access Committee.

Type of data Patient cohort

HCV whole genome sequence data

Publications:

Thomson E et al ‘Comparison of next generation sequencing technologies for the comprehensive assessment of full-length hepatitis C viral genomes’Journal of Clinical Microbiology 2016 54 (10): 2470-84

Ansari MA, Pedergnana V et al ‘A genome-to-genome analysis shows the impact of the innate and adaptive immune system on the hepatitis C virus’Nat Genet. 2017 49(5): 666-673

Ansari MA et al “Interferon lambda 4 impacts the genetic diversity of hepatitis C virus.” Elife. 2019 Sep 3;8. pii: e42463. doi: 10.7554/eLife.42463.

Smith D et al ‘Resistance analysis of genotype 3 HCV reveals subtypes inherently resistant to NS5A inhibitors’.Hepatology. 2019 May; 69(5):1861-1872. doi: 10.1002/hep.29837. Epub 2018 Apr 27

BOSON study (n=601)

Foster GR et al. ‘Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection’ Gastroenterology 2015, 149(6): 1462-70

HCV Research UK (n>12,000; ~1,000 patients with HCV WGS data)

McLauchlan J et al. ‘Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank.’ Int J Epidemiol. 2017 Oct 1;46(5):1391-1391h

STOP-HCV Cirrhosis Study (subset of HCV Research UK cohort; n=1,254)

NHS England Early Access DAA programme (n=806)

Foster GR, Irving WI et al. ‘Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis’. J Hepatology 2016; 64(6): 1224-1231

STOP-HCV1 (n=202)

Host genotyping data - generated using Affymetrix UK Biobank array

Publications:

Ansari MA, Pedergnana V et al ‘A genome-to-genome analysis shows the impact of the innate and adaptive immune system on the hepatitis C virus’Nat Genet. 2017 49(5): 666-673

Pedergnana V et al. ‘Impact of IFNL4 genetic variants on sustained virologic response and vireamia in hepatitis C virus genotype 3 patients’ J Interferon Cytokine Res. 2019 Jul 1. Doi: 10.1089/jir.2019.0013

Ansari MA et al “Interferon lambda 4 impacts the genetic diversity of hepatitis C virus.” Elife. 2019 Sep 3;8. pii: e42463. doi: 10.7554/eLife.42463.

BOSON study (n=601)

Foster GR et al. ‘Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection’ Gastroenterology 2015, 149(6): 1462-70

HCV Research UK (n>12,000; ~3,500 patients with HCV WGS data)

McLauchlan J et al. ‘Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank.’ Int J Epidemiol. 2017 Oct 1;46(5):1391-1391h

STOP-HCV Cirrhosis Study (subset of HCV Research UK cohort; n=1,254)

NHS England Early Access DAA programme (n=806)

Foster GR, Irving WI et al. ‘Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis’. J Hepatology 2016; 64(6): 1224-1231

STOP-HCV1 (n=202)

RNAseq data

Publications:

Ramamurthy N et al ‘Impact of IFNL4 genotype on Interferon-stimulated Gene Expression during DAA therapy for Hepatitis C’ Hepatology. 2018 Mar 13. doi: 10.1002/hep.29877

BOSON study (n=601; ~300 with RNAseq data)

Foster GR et al. ‘Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection’ Gastroenterology 2015, 149(6): 1462-70

Immune phenotyping data

(e.g. cytokine assays, flow cytometry, microbial translocation)

BOSON study (n=601)

Foster GR et al. ‘Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection’ Gastroenterology 2015, 149(6): 1462-70

Biomarker data

(e.g. GALAD scoring, mass spectrometry for fibrosis markers)

NHS England Early Access DAA programme (n=806; ~75 with GALAD scoring)

Foster GR, Irving WI et al. ‘Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis’. J Hepatology 2016; 64(6): 1224-1231

HCV Research UK (n>12,000; ~100 with mass spectrometry data for fibrosis markers)

McLauchlan J et al. ‘Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank.’ Int J Epidemiol. 2017 Oct 1;46(5):1391-1391h
In this section

The Bio-medical Research Council (BRC), a part of the Oxford Hospital Radcliffe Trust (OHRT), funds research and many of our staff are involved in BRC research.

Our research is funded from a variety of funders. Their support allows our research to focus on the basic and clinical research domains to accelerate knowledge translation from the bedside to the bench, and back again.